Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.

Clinical pharmacology and therapeutics - 1 Jun 2009

Wenning L A, Petry A S, Kost J T, Jin B, Breidinger S A, DeLepeleire I, Carlini E J, Young S, Rushmore T, Wagner F, Lunde N M, Bieberdorf F, Greenberg H, Stone J A, Wagner J A, Iwamoto M

Abstract excerpt

Raltegravir is a human immunodeficiency virus-1 (HIV-1) integrase strand transfer inhibitor metabolized by glucuronidation via UDP-glucuronosyltransferase 1A1 (UGT1A1). In this study, 30 subjects with a UGT1A1*28/*28 genotype (associated with decreased activity of UGT1A1) and 27 UGT1A1*1/*1 control subjects (matched by race, age, gender, and body mass index) received a single 400-mg dose of raltegravir after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Half-Life

Share to HIV Integrase Inhibitors

Share to Polymorphism, Single Nucleotide

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 19279563
DOI: 10.1038/clpt.2009.12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.PMID 19279563Read ↗

Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.Semantic proximity Read ↗

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.Semantic proximity Read ↗

Pharmacogenetics of Gilbert's syndrome.Semantic proximity Read ↗

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.Semantic proximity Read ↗

Short communication: lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients.Semantic proximity Read ↗

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.Semantic proximity Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.Semantic proximity Read ↗

Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.